Background Urinary excretion of the low molecular weight protein cystatin C is a marker of renal disorders and a good predictor of the severity of acute tubular necrosis. We evaluated the measurement of urinary cystatin C and determined its reference range.
Introduction
Cystatin C, a 13-kDa endogenous cysteine proteinase inhibitor, is produced by nucleated cells at a constant rate, freely ¢ltered by the glomerulus, reabsorbed and catabolized, but not secreted by the tubules. 1, 2 Serum cystatin C has been recently introduced as a new marker to estimate glomerular ¢ltration rate (GFR) and has demonstrated higher diagnostic value than serum creatinine in detecting reduced GFR. 3 In normal renal function, tubular reabsorption and catabolism of cystatin C is almost complete and cystatin C is only detected in very small quantities in the urine. In healthy controls, urinary cystatin C below 0.30 mg/L was measured by single radial immunodi¡usion. 4 Increased urinary cystatin C was noted especially in renal disorders such as the tubular damage associated with Chinese herbs, HIV nephropathy, and acute interstitial nephritis. 4^8 In a recent study, we demonstrated that the urinary excretion of cystatin C accurately predicts the requirement of renal replacement therapy in acute tubular necrosis (ATN), 4 days preceding the subsequent need for renal replacement therapy. 9 This is important, as ATN requiring renal replacement therapy is associated with a high mortality. 10 The time gained by predicting high-risk ATN patients using urinary cystatin C may help to intensify early supportive care or to initiate potential future therapeutic interventions which may consequently improve the outcome of ATN.
The recently introduced particle-enhanced nephelometric immunoassay (PENIA) has shown excellent performance in the measurement of serum cystatin C. 11^13 In contrast to earlier methods, including enzyme-linked immunosorbent assay (ELISA), cellulose acetate membrane electrophoresis with consecutive silver staining and radial immunodi¡usion,
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PENIA is commercially available and should permit rapid, automated and quantitative measurement of urinary cystatin C. 4, 7, 8, 14 Despite the diagnostic significance of urinary cystatin C, there are few data on analytical performance, interfering factors or reference range of urinary cystatin C analysis. The present study was designed to evaluate the performance of urinary cystatin C measurement by PENIA, to assess potential pre-analytical factors in the urine in£uencing its measurement, and to determine the reference range for urinary cystatin C. (16) years]. In addition, urinary cystatin C was normaliz ed for urine creatinine to compensate for di¡erences in diuresis and timing of urine sampling; the respective reference values were also calculated. 15 Samples from patients with chronic renal failure and from healthy volunteers were from urine collected between 08:00 and 10:00 a.m. Samples from patients with ATN were collected from random, untimed morning urine.
Methods

Patients' samples
Informed consent was obtained from all patients and healthy subjects prior to enrolment in the study.
Assay procedure
Cystatin C was measured in the urine by PENIA (DadeBehring, Marburg, Germany) on a BNA nephelometer (DadeBehring) according to the instructions of the manufacturer. Brie£y, this assay uses rabbit antihuman cystatin C antiserum coated on polystyrene particles. The assay is performed at room temperature with a 6-point calibration curve for cystatin C, generated from multiple dilutions of a human cystatin C calibrator. This calibrator consists of puri¢ed cystatin C from human urine.We performed all measurements in duplicate and took the mean for further analysis. Cystatin C was measured within 3 h, except when stated di¡erently. The detection limit of cystatin C in the urine was 0.05 mg/L, as previously described. 13 Values less than 0.05 mg/L were excluded from further analysis except for testing of analyte stability and reference range, where these values were treated as 0.04 mg/L in the statistical evaluation.
Serum and urinary creatinine concentrations were measured by a modi¢ed Ja¡e method with protein precipitation and an alkaline picrate reaction.
Linearity
Linearity was determined by analysing ¢ve urine samples with expected cystatin C values in the range 0.19-11.93 mg/L. These samples were serially diluted with isotonic saline solution (9 g/L) in order to obtain urinary cystatin C between 10% and 90% of the undiluted sample.
Accuracy and precision
Accuracy of the PENIA was evaluated by 20 analyses of commercially available control material (Dade-Behring), consisting of lyophilized human cystatin C diluted with distilled water to a ¢nal concentration of 1.76 mg/L on consecutive days according to the manufacturer's instruction. The intra-assay precision was assessed using 20 replicate analyses of urine samples of ¢ve patients; the inter-assay precision was assessed by analysing urine samples of these patients over 10 consecutive working days. For inter-assay precision, urinary cystatin C was measured with and without the stabilization bu¡er, which contained 0.006 mmol/ L benzamidine chloride, 0.03 mmol/ L EDTA, 0.05 mmol/ L Tris and 0.015 mmol/ L sodium azide (¢nal concentrations). This bu¡er was previously proposed to prevent the proteolytic degradation of cystatin C in the urine. 14
Analyte stability
Urine samples of the 73 patients with ATN were aliquoted with and without the stabilization bu¡er. Additionally:
1. Urine samples of seven patients with chronic renal insu¤ciency were aliquoted and stored at various temperatures. Cystatin C was measured at the following time points:
. 208C: measurement at 0, 6, 24, 48 and 72 h. . 48C: measurement at 0, 24, 48 and 72 h, and after 7 days. . 7208C: measurement at 0, 24, 48 and 72 h, and after 7 and 28 days.
2. Urine samples of seven patients underwent up to three freeze -thaw cycles before measurement. 3. Urine samples of seven patients were adjusted to pH from 3 to 9 with 1mol/L hydrochloric acid (HCl) or 1mol/ L sodium hydroxide (NaOH) respectively and cystatin C was measured in each pH-adjusted aliquot. 4. Cystatin C was measured in urine samples with an initial pH 5 which were then brought to pH 3 and 4. Immediately, and after storage at 48C for 6 and 24 h, and at 7208C for 1and 7 days, these samples were titrated back to pH 5 and urinary cystatin C was measured. Cystatin C concentration was corrected for the dilution e¡ect of the added HCl and NaOH.
Adsorption
To test for potential adsorption to plastic, we measured cystatin C in freshly voided urine samples from 22 patients and compared these cystatin C concentrations with those from aliquots of the same urine after 6 h of storage in polyvinyl chloride urine collection bags (Sarstedt, Nurnbrecht, Germany).
Interference
The potential interferences of albumin (concentration range 60 -160 g/L), bilirubin (25-500 mmol/L) and haemoglobin (15-210 mmol/L) were assessed by measuring cystatin C in urine samples of seven patients with the respective interfering substance in the above concentrations according to an established protocol. 16
Statistical analysis
Data are presented as mean (SD, range). Measured urinary cystatin C concentrations are expressed either as absolute values or as a percentage of control or expected concentrations. Data were compared by Mann-Whitney rank-sum test. Di¡erences in means between groups were analysed by ANOVA followed by Student-Newman-Keuls multiple comparison procedure. P-values less than 0.05 were considered to be statistically signi¢cant. Comparison between expected and observed cystatin C concentrations for linearity was performed by linear regression analysis, and comparison between cystatin C measurements with and without stabilization bu¡er by the Bland-Altman procedure. 17 The coe¤cient of repeatability, indicating the required di¡erences between both measurements before a statistical di¡erence was presumed, was expressed by 95% limits of agreement; 95% limits of agreement were determined as 1.96 SD of the mean di¡erence of both measurements. We calculated the reference range for urinary cystatin C by a non-parametric method according to International Federation of Clinical Chemistry guidelines. 18
Results
Linearity
Measurement of urinary cystatin C in the range 0.05-10.47 mg/L was linear and did not di¡er signi¢cantly from expected urinary cystatin C values (P50.001) (see Fig. 1 ). The equation derived from regression analysis was yˆ0.99x70.01mg/L (r 2ˆ0 .996, nˆ47) with a standard error of estimate of 0.054. In the measuring range of the assay, the deviation of observed from expected values was 70.5% (3.3%, 78.0-5.5%).
Accuracy and precision
Accuracy, intra-and inter-assay precision were determined on ¢ve urine samples covering the entire range of urinary cystatin C concentrations (0.10-11.48 mg/ L). Accuracy was below the 20% margin (cystatin C 1.41-2.11 mg/ L) proposed by the manufacturer. Accuracy expressed as the di¡erence between the expected and the measured values of cystatin C control material was 70.8% (2.6%, 77.4 -4.6%). The intra-assay imprecision averaged 2.9% and never exceeded 5.0% (see Table 1 ). The inter-assay imprecision averaged 4.6% and did not exceed 5.2% in samples without stabilization bu¡er, and averaged 6.9% and did not exceed 7.4% in samples with bu¡er (see Table 1 ). Urinary cystatin C concentrations in samples with the addition of stabilization bu¡er did 
Analyte stability Stabilization buffer
Cystatin C concentrations measured in urine samples with and without stabilization bu¡er di¡ered by a mean of 70.01 (0.15) mg/L, which corresponded to a 4.8% (3.7%, 0-11.7%) di¡erence between urinary cystatin C measurement with and without stabilization (see Fig. 2 ). Ninety-¢ve per cent limits of agreement were close, with a range of 70.31-0.29 mg/L. This high degree of agreement between urinary cystatin C measurement with and without stabilization bu¡er was present over the entire range of cystatin C concentrations tested (0.15-6.15 mg/ L). Inter-assay imprecision was determined from aliquots of the same samples with and without the addition of stabilization buffer. SD, standard deviation; CV, coef cient of variation. pH Cystatin C was stable in urine in the pH range 5-9 (see Fig. 3 ). Urinary cystatin C concentration at pH 5 in the range 0.69-11.01 mg/L was de¢ned as 100%. The cystatin C concentration at pH 4 was reduced to 73.4% (14.7%, 55.1-96.1%) (P50.05). At pH 3, urinary cystatin C further decreased to 14.7% (3.2%, 9.4 -17.6%) (P50.01). When urine was titrated back from pH 4 to pH 5 immediately or after storage at 48C for 6 h, cystatin C concentrations were only moderately reduced compared to initial values (see Table 2 ). However, as demonstrated in Table 2 , signi¢cantly lower cystatin C concentrations were measured in samples titrated back from pH 4 to pH 5 after 24 h at 48C, or after 1 and 4 weeks storage at 7208C. When titrated back from pH 3 to 5 immediately or after 6 h at 48C, there was only a minor increase of cystatin C concentrations and initial values were not reached. Urinary cystatin C also remained signi¢cantly reduced when urine was titrated back to pH 5 after 24 h of storage at pH 3 (see Table 2 ).
Adsorption
No adsorption of cystatin C to the surface of plastic urine collection bags was observed. Urine cystatin C concentrations in freshly voided samples, ranging from 0.33 to 10.65 mg/L, di¡ered by 0.01 (0.08, 70.24 -0.35) mg/L from aliquots stored in urine collection bags for 6 h (Pˆnot signi¢cant).
Interference
Addition of albumin, bilirubin and haemoglobin did not substantially interfere with the measurement of cystatin C in the urine (see Table 3 ). The mean recovery of cystatin C (range 0. bilirubin or haemoglobin did not statistically di¡er from urinary cystatin C values in control samples.
Reference range
We determined an upper reference value for urinary cystatin C of 0.28 mg/L in urine samples from 133 healthy volunteers. The distribution of urinary cystatin C in these controls is shown in Fig. 4 . The upper reference value did not di¡er between women and men (0.27 mg/L versus 0.28 mg/L). Lower reference values are not presented due to the detection limit of 0.05 mg/L. When normalized for urinary creatinine, the upper reference value was 0.04 mg/mmol urinary creatinine for 120 healthy volunteers with urinary cystatin C 50.05 mg/L. Age did not alter urinary cystatin C and there was no correlation between age and urinary cystatin C (r 2ˆ0 .04, Pˆ0.61).
Discussion
Measurement of cystatin C in the urine by PENIA performed well with high precision and good linearity. We demonstrated that the measurement of urinary cystatin C by PENIA is precise with small intra-and inter-assay variation. The intra-and inter-assay variations for the measurement of urinary cystatin C determined by us are consistent with the precision previously reported for measurement of serum cystatin C by PENIA and of urinary cystatin C by ELISA. 7, 11, 12 Assessment of linearity for the measurement of cystatin C by PENIA in the lower range of cystatin C concentrations was necessary as previous studies only evaluated linearity for cystatin C concentrations far above the values that are present in healthy individuals. 11^13 Furthermore, cystatin C measurement by PENIA was accurate. However, no control material to test accuracy of cystatin C measurement in the urine was available and our data on accuracy resulted from control material designed for serum measurements. Cystatin C demonstrated good stability in urine under most routine storage conditions. In particular, cystatin C was stable for 48 h at room temperature, and for 1 week at 48C and at 7208C. This increases its practicability as a routine biochemical parameter. In general, the stability of cystatin C in urine is in agreement with previous data on its stability in urine and serum. 7, 11, 12 Repeated freezing and thawing of samples did not a¡ect the measured levels of cystatin C in the urine. Furthermore, cystatin C was stable in the urine at pH 5 or above. This is of clinical importance as urine pH 5 or above is common; of 500 consecutive urine samples examined in our laboratory, 98.4% had a pH of 5 or above (unpublished data). Decreased cystatin C concentrations at pH 4 were partially reversible when the urine pH returned to 5 within 6 h. Thus, minor acidity for shorter time periods potentially causes reversible structural changes in cystatin C that interfere with its measurement by PENIA. As urinary cystatin C remained low at pH 4 for 24 h and generally at pH 3, structural changes to cystatin C may become permanent when the pH is 4 for longer time periods or below pH 4. Our data indicate that cystatin C is stable in urine and that stabilization bu¡er is not required when cystatin C is measured in the urine. This result di¡ers considerably from a previous study with a small sample size, which reported proteolytic degradation of cystatin C in the urine and proposed that cystatin C should be stabilized in the urine before measurement. 14 Unfavourable storage conditions or bacterial contamination may have accounted for decreased cystatin C concentrations in unadulterated urine previously observed by others. 14 Additionally, we did not observe any marked adsorption of cystatin C to polyvinyl chloride, a material that is a commonly used for urine collection bags. Furthermore, endogenous substances that are potentially present in the urine such as albumin, bilirubin or haemoglobin showed only negligible interference with the measurement of urinary cystatin C by PENIA. Neither grossly proteinuric, icteric nor haemolytic samples a¡ected measurement of cystatin C concentrations in the urine. The good overall stability and the lack of interference or adsorption to polyvinyl chloride simpli¢es sample collection and handling as cystatin C may be measured in urine samples collected under most routine clinical conditions. However, we recommend that cystatin C should not be measured in urine samples stored at room temperature for more than 48 h, at 48C and at 7208C for more than 1week or at a urine pH below 5.
According to the upper reference value proposed by us, only small concentrations of cystatin C are present in the urine of healthy controls. This reference value for urinary cystatin C corresponds well with those previously published. 4, 7 The detection limit of 0.05 mg/ L for urinary cystatin C by PENIA seems adequate, as it is at the lower end of the potential reference range. As upper reference values for urinary cystatin C were independent of age and gender, a single reference range seems appropriate. Although our study includes a typical cross-section of healthy controls and patients with renal disorders covering a wide range of cystatin C concentrations in the urine, further studies in more comprehensive cohorts are required to establish de¢nite reference values for urinary cystatin C measured by PENIA.
Cystatin C has advantages as a urinary marker of tubular injury compared to established markers such as a 1 -microglobulin, b 2 -microglobulin and retinolbinding protein. 9 In contrast to b 2 -microglobulin, infection, in£ammation and malignancy do not increase the urinary concentration of cystatin C as cystatin C is produced and ¢ltered at a constant rate. 1,2,19^22 In addition, cystatin C is more stable in the urine than a 1 -microglobulin, b 2 -microglobulin or retinol-binding protein are and may have age-and gender-independent reference values. 23^26 These advantages may promote the widespread use of urinary cystatin C as a marker of tubular injury in clinical practice.
In conclusion, the measurement of cystatin C in the urine by PENIA achieved a good performance. This method o¡ers rapid, automated and precise measurement of cystatin C in comparison to earlier methods which were slower, semi-quantitative, less precise, or not commercially available. 4, 7, 8, 14 Additional bene¢ts are the high stability of urinary cystatin C, the lack of interference and the lack of variability with the method of urine collection, age and gender. These features are particularly important when urinary cystatin C is used as a routine biochemical test of tubular injury in clinical practice.
